Anifrolumab Interactions
There are 214 drugs known to interact with anifrolumab, along with 1 disease interaction. Of the total drug interactions, 42 are major, 165 are moderate, and 7 are minor.
- View anifrolumab disease interactions (1)
Medications known to interact with anifrolumab
Note: Showing generic names only.
A
- abatacept
- abrocitinib
- acalabrutinib
- adalimumab
- adenovirus vaccine
- alefacept
- alemtuzumab
- allogeneic processed thymus tissue
- anakinra
- anthrax vaccine adsorbed
- azathioprine
B
- baricitinib
- basiliximab
- bcg
- bcg vaccine
- belantamab mafodotin
- belimumab
- belinostat
- bevacizumab
- bifidobacterium infantis
- bimekizumab
- blinatumomab
- bortezomib
- brentuximab
- brewer's yeast
- brodalumab
C
- canakinumab
- candida albicans extract
- carfilzomib
- cat's claw
- certolizumab
- chikungunya vaccine, live (cvx 317)
- cholera vaccine
- cholera vaccine, live
- cladribine
- coccidioidin skin test
- copanlisib
D
- daratumumab
- dengue vaccine
- denosumab
- deucravacitinib
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- duvelisib
E
- echinacea
- eculizumab
- efalizumab
- efgartigimod alfa
- elotuzumab
- elranatamab
- enfortumab vedotin
- epcoritamab
- etanercept
- etrasimod
F
G
H
- haemophilus b conjugate (hboc) vaccine
- haemophilus b conjugate (prp-omp) vaccine
- haemophilus b conjugate (prp-t) vaccine
- hepatitis a adult vaccine
- hepatitis a pediatric vaccine
- hepatitis b adult vaccine
- hepatitis b pediatric vaccine
- histoplasmin
- human papillomavirus vaccine
I
- ibritumomab
- ibrutinib
- idelalisib
- inebilizumab
- infliximab
- influenza virus vaccine, h1n1, inactivated
- influenza virus vaccine, h1n1, live
- influenza virus vaccine, h5n1
- influenza virus vaccine, inactivated
- influenza virus vaccine, live
- inotuzumab ozogamicin
- interferon beta-1a
- interferon beta-1b
- ixazomib
- ixekizumab
J
L
- lactobacillus acidophilus
- lactobacillus reuteri
- lactobacillus rhamnosus
- lactobacillus rhamnosus gg
- leflunomide
- loncastuximab tesirine
- lyme disease vaccine
M
- measles virus vaccine
- meningococcal conjugate vaccine
- meningococcal group acwy conjugate-group b vaccine (cvx 316)
- meningococcal group B vaccine
- meningococcal polysaccharide vaccine
- mirikizumab
- mixed respiratory vaccine
- mogamulizumab
- monomethyl fumarate
- mumps skin test antigen
- mumps virus vaccine
N
O
P
- panobinostat
- peginterferon beta-1a
- pertussis, acellular
- plague vaccine
- pneumococcal 13-valent vaccine
- pneumococcal 15-valent conjugate vaccine
- pneumococcal 20-valent conjugate vaccine
- pneumococcal 23-polyvalent vaccine
- pneumococcal 7-valent vaccine
- polatuzumab vedotin
- poliovirus vaccine, inactivated
- poliovirus vaccine, live, trivalent
- ponesimod
- pozelimab
R
- rabies vaccine, human diploid cell
- rabies vaccine, purified chick embryo cell
- ravulizumab
- rilonacept
- risankizumab
- ritlecitinib
- rituximab
- roflumilast
- romidepsin
- rotavirus vaccine
- rozanolixizumab
- rsv vaccine pref3, recombinant
- rsv vaccine, pref a-pref b, recombinant
- rubella virus vaccine
S
- saccharomyces boulardii lyo
- sacituzumab govitecan
- sarilumab
- sars-cov-2 (covid-19) ad26 vaccine, recombinant
- sars-cov-2 (covid-19) chadox1 vaccine, recombinant
- sars-cov-2 (covid-19) mrna (tozinameran 12y+) bivalent booster vaccine
- sars-cov-2 (covid-19) mrna (tozinameran 5y-11y) bivalent booster vaccine
- sars-cov-2 (covid-19) mrna (tozinameran 6m-4y) bivalent booster vaccine
- sars-cov-2 (covid-19) mrna (tozinameran 6m-4y) bivalent vaccine
- sars-cov-2 (covid-19) mrna-1273 (6m-5y bivalent booster) vaccine
- sars-cov-2 (covid-19) mrna-1273 (bivalent booster) vaccine
- sars-cov-2 (covid-19) mrna-1273 bivalent vaccine
- sars-cov-2 (covid-19) mrna-1273 vaccine
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 308)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 309)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 310)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 311)
- sars-cov-2 (covid-19) mrna-lnp vaccine (cvx 312)
- sars-cov-2 (covid-19) mrna(tozinameran12y+) bivalent vaccine
- sars-cov-2 (covid-19) nvx-cov2373 vaccine, recombinant
- sars-cov-2 (covid-19) rs-nanoparticle vaccine, recombinant
- sars-cov-2 (covid-19)mrna-1273(6y+ bivalent booster) vaccine
- sars-cov-2 mrna (tozinameran 5y-11y) vaccine
- sars-cov-2 mrna (tozinameran 6m-4y) vaccine
- sars-cov-2 mrna (tozinameran-tris-sucrose) vaccine
- sars-cov-2 mrna (tozinameran) vaccine
- sars-cov-2 mrna-1273 (6m-5y) vaccine
- sars-cov-2 mrna-1273 (6y-11y) vaccine
- sars-cov-2 mrna-1273 (booster only) vaccine
- sars-cov-2 nvx-cov2373 vaccine, recomb (cvx 313)
- sars-cov-2 pres dtm (booster only) vaccine, recombinant
- sars-cov-2(covid-19)mrna(tozinameran 5y-11y)bivalent vaccine
- satralizumab
- secukinumab
- siltuximab
- siponimod
- sipuleucel-T
- skin test antigens, multiple
- smallpox and monkeypox vaccine
- smallpox vaccine
- spesolimab
- staphage lysate (spl)
- sutimlimab
T
- tafasitamab
- talimogene laherparepvec
- talquetamab
- teclistamab
- teriflunomide
- tetanus toxoid
- tick-borne encephalitis (inactivated) pediatric vaccine
- tick-borne encephalitis (inactivated) vaccine
- tildrakizumab
- tocilizumab
- tofacitinib
- trichophyton skin test
- tuberculin purified protein derivative
- typhoid vaccine, inactivated
- typhoid vaccine, live
U
V
Y
Z
- zanubrutinib
- zinc acetate
- zinc chloride
- zinc gluconate
- zinc sulfate
- zoster vaccine live
- zoster vaccine, recombinant
Anifrolumab disease interactions
There is 1 disease interaction with anifrolumab which include:
More about anifrolumab
- anifrolumab consumer information
- Compare alternatives
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.